Claudio Jommi

Government, Health and Not for Profit


Latest publications

Ronco V., Dilecce M., Lanati E., Canonico P. L., JOMMI C. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? Journal of Pharmaceutical Policy and Practice, 2021, vol.14, no. 1, pp.30
ROGNONI C., BERTOLANI A., JOMMI C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects Clinical Drug Investigation, 2021, vol.41, no. 4, pp.303-319
Galeone C., Bruzzi P., JOMMI C. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system BMJ Open, 2021, vol.11, no. 1, pp.e041259
Pruneri G., De Braud F., Sapino A., Aglietta M., Vecchione A., Giusti R., Marchiò C., Scarpino S., Baggi A., Bonetti G., Franzini J. M., Volpe M., JOMMI C. Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? PharmacoEconomics - Open, 4 March, 2021
JOMMI C., ARMENI P., BERTOLANI A., COSTA F., OTTO M. The future of Funds for Innovative Medicines: results from a Delphi Study Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2021, vol.8, pp.22-28
ARMENI P., BORSOI L., FORNARO G., JOMMI C., COLOMBO N., COSTA F. Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service Clinical Therapeutics, 2020, vol.42, no. 7, pp.1192-1209

Grants & Honors

Management of funds for innovative medicines - MSD Oncology , 2020
Valuation of the EQ-5D-5L in Italy - EuroQol Research Foundation , 2019

Related Articles

Striking the right balance between value and price in pha...
Required time 6 min


Master of International Healthcare Management, Economics and Policy
Language ENGLISH
Total duration One year
Start date 26 Sep 2021